Pair page
Semaglutide with VK2735
Mechanism-tag overlap and published literature for Semaglutide and VK2735, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
glp-1-receptor-agonistmetabolic
dual-gip-glp-1-receptor-agonistviking-therapeutics
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Semaglutide and VK2735 have published these mechanism-level observations. Not a co-administration recommendation.
Not a stack — selective GLP-1 agonist. Class competitor. Transition considerations, not combination.
Quick facts
Semaglutide
VK2735
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2024 | Semaglutide | Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. PMID: 38785209. PMID 38785209 | human trial |
| 2023 | Semaglutide | Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. PMID 37952131 | human trial |
| 2022 | Semaglutide | Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. PMID: 36216945. PMID 36216945 | human trial |
| 2022 | Semaglutide | Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022;327(2):138-150. PMID: 35015037. PMID 35015037 | human trial |
| 2021 | Semaglutide | Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. PMID 33567185 | human trial |
| 2021 | Semaglutide | Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PMID: 33667417. PMID 33667417 | human trial |
| 2021 | Semaglutide | Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. PMID: 33625476. PMID 33625476 | human trial |
| 2021 | Semaglutide | Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414-1425. PMID: 33755728. PMID 33755728 | human trial |
| 2021 | Semaglutide | Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. PMID: 33185364. PMID 33185364 | human trial |
| 2019 | Semaglutide | Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(9):1724-1732. PMID: 31186300. PMID 31186300 | human trial |
| 2016 | Semaglutide | Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6). N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186. PMID 27633186 | human trial |
| 2019 | Semaglutide | Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155. PMID: 31031702. PMID 31031702 | mechanism / discovery |
| 2024 | VK2735 | Viking Therapeutics. Corporate presentations and SEC filings, 2024–2026, detailing VK2735 Phase 2 data, oral formulation development, and anticipated Phase 3 timeline. | human trial, Phase 3 |
| 2024 | VK2735 | Viking Therapeutics. VK2735 Phase 2 (VENTURE) topline results: 13-week weight-loss data in adults with obesity. Press release and investor presentations, 2024. | human trial, Phase 2 |
| 2024 | VK2735 | Bays HE, Kelly AS, Aronne LJ, et al. Weekly subcutaneous VK2735 for weight management in adults with obesity — Phase 2 VENTURE trial. ObesityWeek 2024 / Obesity (Silver Spring). 2024. | human trial, Phase 2 |
| 2024 | VK2735 | Viking Therapeutics. Phase 1 and Phase 2 oral VK2735 program: pharmacokinetics and early weight-loss signal. 2024–2025 communications. | human trial, Phase 2 |
| 2023 | VK2735 | Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. PMID 37366315 | human trial, Phase 2 |
| 2023 | VK2735 | Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group… PMID 37385275 | human trial, Phase 2 |
| 2022 | VK2735 | Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024. PMID 35658024 | human trial |
| 2021 | VK2735 | Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al.; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647. PMID 34170647 | human trial |
| — | VK2735 | ClinicalTrials.gov. A Study of VK2735 in Participants With Obesity (VENTURE). NCT05946356. | human trial |
| 2022 | VK2735 | Viking Therapeutics. Phase 1 pharmacokinetics, safety, and tolerability of subcutaneous VK2735 in healthy and obese volunteers. 2022–2023. | human trial, Phase 1 |
| 2023 | VK2735 | Wharton S, Astrup A, Endahl L, Lean MEJ, Satylganova A, Skovgaard D, Wadden TA. Oral semaglutide for the treatment of obesity. Lancet. 2023;402(10403):653-656. (Oral semaglutide class context.) | human study |
| 2018 | VK2735 | Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PMID: 30473097. PMID 30473097 | mechanism / discovery |
Related pair pages
More research context
Frequently asked
Have Semaglutide and VK2735 been studied together?
Researchers have published mechanistic-level co-administration discussion of Semaglutide and VK2735. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Semaglutide and VK2735 share?
Semaglutide and VK2735 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Semaglutide and VK2735?
Semaglutide: Approved (2017). VK2735: Investigational (Phase 2). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Semaglutide and VK2735?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Semaglutide profile and the VK2735 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026